SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC

767 F.3d 1339, 112 U.S.P.Q. 2d (BNA) 1198, 2014 U.S. App. LEXIS 17830, 2014 WL 4627594
CourtCourt of Appeals for the Federal Circuit
DecidedSeptember 17, 2014
Docket2013-1564
StatusPublished
Cited by10 cases

This text of 767 F.3d 1339 (SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC, 767 F.3d 1339, 112 U.S.P.Q. 2d (BNA) 1198, 2014 U.S. App. LEXIS 17830, 2014 WL 4627594 (Fed. Cir. 2014).

Opinion

HUGHES, Circuit Judge.

SCA owns U.S. Patent No. 6,375,646 (the '646 patent), which relates to certain adult incontinence products. After SCA sued a competitor, First Quality, for infringement of the '646 patent, the district court dismissed the case, finding that SCA’s claims were barred by both laches and equitable estoppel. Because the district court properly concluded that SCA’s more than six-year delay in filing suit warranted dismissal based on laches, we affirm the court’s grant of summary judgment in that regard. But given SCA and First Quality’s limited interactions, there remain genuine issues of material fact pertaining to equitable estoppel. Accordingly, we reverse the district court’s grant of summary judgment as to equitable estop-pel and remand for further proceedings consistent with this opinion.

I

SCA 1 and First Quality 2 compete in the market for adult incontinence products. On October 31, 2003, SCA sent a letter to *1342 First Quality, suggesting that certain First Quality products might infringe the '646 patent. The letter stated:

It has come to our attention that you are making, selling and/or offering for sale in the United States absorbent pants-type diapers under the name Prevail® All NitesTM. We believe that these products infringe claims of [the '646 patent].
We suggest that you study [the '646 patent]. If you are of the opinion that the First Quality Prevail® All NitesTM absorbent pants-type diaper does not infringe any of the claims of this patent, please provide us with an explanation as to why you believe the products do not infringe. If you believe that the products do infringe, please provide us with your assurance that you will immediately stop making and selling such products.

J.A. 544. First Quality responded on November 21, 2003, and stated:

As you suggested, we studied [the '646 patent],... In addition, we made a cursory review of prior patents and located U.S. Patent No. 5,415,649, (“the '649 Patent”), which was filed in the United States on October 29,1991 and is therefore prior to your client’s '646 Patent. A review of Figs. 3 and 4 of the prior '649 Patent reveals the same diaper construction claimed by the '646 Patent. Thus, the prior '649 Patent invalidates your client’s '646 Patent. As you know, an invalid patent cannot be infringed.

J.A. 547. These two communications were the only instances in which either party mentioned the '646 patent. SCA and First Quality exchanged four more brief letters over the next eight months before ceasing communications, but those letters concerned a different patent and different First Quality products.

On July 7, 2004—one day after SCA sent its final communication to First Quality—SCA filed an ex parte reexamination request for the '646 patent. SCA asked the United States Patent and Trademark Office (PTO) to review the patentability of the '646 patent in light of the '649 patent and European Patent Application No. 0187727 A2. About three years later, on March 27, 2007, the PTO confirmed the patentability of all 28 original claims and issued several new claims added during reexamination.

SCA never notified First Quality about the reexamination proceedings. According to SCA, it believed it was under no obligation to do so because the PTO provides public notice of all reexaminations. See 37 C.F.R. §§ 1.11(c), 1.570(f). First Quality, meanwhile, stated that it no longer considered the '646 patent “to be an issue” after making its invalidity allegations. SCA Hygiene Prods. AB v. First Quality Baby Prods., LLC, No. 10-cv0122, 2013 WL 3776173, at *10 (W.D.Ky. July 16, 2013) (internal quotation marks omitted).

Starting in 2006, while the '646 patent was under reexamination, First Quality began expanding its line of adult incontinence products. In 2008, after the reexamination had concluded, First Quality acquired Covidian’s Tyco Healthcare Retail Group LP and, along with it, some of the products at issue in this case. It continued its expansion in 2009 at a cost of more than $10 million.

SCA claims that it began preparing to file suit against First Quality immediately after the reexamination certificate issued in March 2007. But SCA did not file suit or otherwise contact First Quality until August 2, 2010, when it filed its complaint in this case—about six years and nine months after SCA first contacted First Quality about the '646 patent. According *1343 to SCA, it spent more than three years after the reexamination concluded implementing new business management structures, evaluating outside counsel, and examining potentially infringing products on the market.

First Quality counterclaimed for declaratory judgments of noninfringement and invalidity. After the district court’s claim construction order, First Quality moved for partial summary judgment of nonin-fringement and for summary judgment of laches and equitable estoppel. The district court granted First Quality’s motion for summary judgment as to laches and equitable estoppel and dismissed the remaining motion as moot.

SCA appeals. We have jurisdiction under 28 U.S.C. § 1295(a)(1).

II

A

Laches is an equitable defense to patent infringement that may arise only when an accused infringer proves by a preponderance of evidence that a patentee (1) unreasonably and inexcusably delayed filing an infringement suit (2) to the material prejudice of the accused infringer. A.C. Aukerman Co. v. R.L. Chaides Constr. Co., 960 F.2d 1020, 1028-29, 1045 (Fed.Cir.1992) (en banc). If these prerequisite elements are present, a court must then balance “all pertinent facts and equities,” including “the length of delay, the seriousness of prejudice, the reasonableness of excuses, and the defendant’s conduct or culpability” before granting relief. Id. at 1034. When found, laches bars retrospective relief for damages accrued prior to filing suit but does not bar prospective relief. Id. at 1041.

Delays exceeding six years give rise to a presumption that the delay is unreasonable, inexcusable, and prejudicial. Wanlass v. Gen. Elec. Co., 148 F.3d 1334, 1337 (Fed.Cir.1998). Under this presumption, the burden of evidentiary production shifts from the accused infringer to the patentee. Id.; see also Fed.R.Evid. 301; Aukerman, 960 F.2d at 1035-36. Both of these presumptions disappear if the paten-tee can identify evidence sufficient for a reasonable jury to conclude either that the delay was excusable or not unreasonable, or that it was not materially prejudicial. See Wanlass, 148 F.3d at 1337.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
767 F.3d 1339, 112 U.S.P.Q. 2d (BNA) 1198, 2014 U.S. App. LEXIS 17830, 2014 WL 4627594, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sca-hygiene-products-aktiebolag-v-first-quality-baby-products-llc-cafc-2014.